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ABSTRACT
Introduction: The objective of this study was to
observe the patterns of usage, efficacy, and
safety of tocilizumab (TCZ) in clinical practice
in patients with rheumatoid arthritis.
Methods: Data on the real-world usage, effi-
cacy, and safety of TCZ were collected from
patients during routine follow-up visits con-
ducted over a 6-month period. Patients were
grouped by previous exposure to biologic ther-
apies (biologic exposed vs. biologic naive).
Results: Of 1912 patients enrolled from 16
countries, 639 (33.4%) received TCZ
monotherapy and 1273 (66.6%) received TCZ
combination therapy. At baseline, 1073 patients
(56.1%) were biologic naive and 839 (43.9%)
were biologic exposed. At 6 months, 1504
patients (78.7%) continued to receive TCZ
treatment, with no descriptive differences in
retention rates between biologic-exposed and
biologic-naive patients and between patients
receiving TCZ monotherapy or combination
therapy. Dose and use of methotrexate and
prednisone were reduced at 6 months. Efficacy
at 6 months, including patient-reported out-
comes, was demonstrated in both biologic-
naive and biologic-exposed groups. Adverse
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events (AEs) occurred in 817 patients [42.7%;
incidence rate: 179 events per 100 patient-years
(PY)], and serious AEs (SAEs) occurred in 118
patients (6.2%; 17 events per 100 PY), with
comparable rates of AEs and SAEs between
subgroups.
Conclusion: In routine clinical practice, TCZ
discontinuation rates were low and unaffected
by prior use of biologics. Effectiveness was
similar between groups, and no new safety sig-
nals were identified.
Funding: F. Hoffmann-La Roche.
Keywords: ACT-UP; Biologic factors;
Rheumatoid arthritis; Tocilizumab
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic and
debilitating autoimmune disease characterized
by inflammation of the joints [1]. Treatment of
RA seeks to alleviate disease signs and symp-
toms, including pain and inflammation, to
reduce joint damage, to preserve function and
quality of life (QOL), and to prevent premature
mortality associated with this disorder [2]. First-
line treatments for RA include conventional
synthetic disease-modifying antirheumatic
drugs (csDMARDs) such as methotrexate (MTX)
[3]; however, many patients have an inadequate
response to MTX and other csDMARDs. In these
patients, the addition of a biologic therapy is
recommended. Although tumor necrosis factor
alpha inhibitors (TNFis) are often the first
choice for a biologic therapy, 30–40% of
patients may not respond to TNFi treatment
[4–6]. In these patients, a biologic with a dif-
ferent mechanism of action may be more
effective.
The biologic DMARD tocilizumab (TCZ) is a
humanized monoclonal antibody targeting the
interleukin-6 receptor. TCZ is approved world-
wide for the treatment of RA in patients who
have had an inadequate response to one or
more csDMARDs and, in the European Union,
in patients who are MTX naive [7, 8]. TCZ has
demonstrated efficacy in patients with an
inadequate response to csDMARDs or TNFis
[9–12] and in patients who are MTX naive
[13, 14], and it has been shown to be effective
when administered as monotherapy or in
combination with MTX [15–18].
We previously reported that in routine clin-
ical practice, patients had a high rate of persis-
tence with both TCZ monotherapy and TCZ
plus csDMARDs [19]. This finding was coupled
with a high rate of efficacy with both treatment
protocols. Our current study describes real-
world information on the patterns of usage of
TCZ in patients with RA with regard to drug
persistence and adherence to the licensed label
recommendations for TCZ. This study expands
on our previous report [19], with a complete
data set containing information collected from
576 additional patients. Furthermore, this
analysis describes patient-reported outcomes
(PROs) and differences in outcomes among




Global analysis was performed on data pooled
from independent local studies contributing to
the ACT-UP umbrella project, which were con-
ducted in 16 countries and shared similar
designs, patient selection criteria, and core data.
Patients with RA initiating intravenous TCZ
were followed up over a 6-month observation
period. The dose of TCZ and duration of treat-
ment were determined according to the inves-
tigator’s judgment and in accordance with the
label and local regulations. The eligibility cri-
teria for participation have been described [19].
Briefly, participants were C 18 years of age, had
a diagnosis of moderate to severe RA according
to the revised (1987) American College of
Rheumatology criteria [20], and had received
TCZ for\ 8 weeks prior to the enrollment visit.
All procedures performed in studies involving
human participants were in accordance with
the 1964 Helsinki Declaration and its later
amendments or comparable ethical standards.
Informed consent was obtained from all indi-
vidual participants included in the study. As
ACT-UP was an umbrella study, the study
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protocols, amendments, and informed consent
documentation were approved by the respective
local institutional review boards or independent
ethics committees of the investigational
centers.
Assessments
Data were collected over a 6-month period on
TCZ efficacy, safety, and patterns of use.
Assessment of efficacy was evaluated using Dis-
ease Activity Score 28 (DAS28) scores. Addi-
tional efficacy end points of interest were QOL
and disability measures, including Patient Glo-
bal Assessment of Disease Activity, Health
Assessment Questionnaire-Disability Index
(HAQ-DI), and visual analog scales to evaluate
the severity of fatigue, pain, and morning stiff-
ness. Adverse events (AEs) and serious AEs
(SAEs) were recorded to evaluate safety and were
collected and reported by system organ class.
When available, laboratory results were evalu-
ated for clinically significant abnormalities.
Statistical Analysis
Data from all 16 countries were pooled for
analysis. Patients were stratified into groups
based on treatment (TCZ monotherapy vs. TCZ
combination therapy) and on biologic exposure
at baseline (naive vs. exposed). Baseline values
could be evaluated prior to the first TCZ treat-
ment. Analyses were primarily performed using
descriptive statistical methods. For Kaplan-
Meier estimates, 95% CIs were computed.
RESULTS
Patient Disposition and Baseline
Characteristics
A total of 1912 patients were enrolled in 16
countries (Table S1), of whom 1073 (56.1%)
were biologic naive and 839 (43.9%) were bio-
logic exposed (Fig. 1) Overall, 1504 patients
(78.7%) completed the study at month 6. The
mean (SD) duration of TCZ treatment was 192.3
(83.0) days. More patients received combina-
tion therapy (1273 patients; 66.6%) than TCZ
monotherapy (639 patients; 33.4%). A total of
Fig. 1 Patient disposition. AE adverse event, SAE serious adverse event
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895 patients (46.8%) received concomitant
corticosteroids.
Baseline demographics and disease charac-
teristics were similar between patients who were
biologic naive and those who were biologic
exposed at baseline and between those receiv-
ing TCZ monotherapy and those receiving
combination therapy (Table 1).
TCZ Retention
Overall, 359 patients (18.8%) discontinued TCZ
during the study. Kaplan-Meier curves for per-
sistence are shown in Fig. 2. A total of 199 bio-
logic-naive patients (18.6%) and 160 biologic-
exposed patients (19.1%) discontinued TCZ;
Kaplan-Meier estimates for the proportions of
patients still receiving TCZ at 24 weeks were
81.3% (95% CI, 78.7–83.7%) for biologic-naive
patients and 82.3% (95% CI, 79.4–84.7%) for
biologic-exposed patients (Fig. 2a). A total of
147 patients (23.0%) receiving TCZ monother-
apy and 212 patients (16.7%) receiving combi-
nation therapy discontinued TCZ; Kaplan-Meier
estimates for the proportions of patients still
receiving TCZ at 24 weeks were 78.3% (95% CI,
74.8%–81.4%) for TCZ monotherapy and 83.5%
(95% CI, 81.2%–85.5%) for TCZ combination
therapy (Fig. 2b). Of 407 patients enrolled in
China (the country with the largest proportion
of enrolled patients; Table S1), 296 patients
completed the study and 111 discontinued the
study prematurely. The primary reason for pre-
mature discontinuation of TCZ in China was
treatment costs.
Concomitant Treatments
A total of 1353 patients (70.8%) received C 1
DMARD during the study period (Table 2). The
most common DMARDs were MTX (56.0%),
leflunomide (22.9%), hydroxychloroquine
(20.8%), and sulfasalazine (10.9%). Of patients
receiving TCZ, 914/1912 (47.8%) received con-
comitant MTX at baseline, and 647/1504
(43.0%) received concomitant MTX at month 6.
Of the patients receiving MTX, mean (SD) dose
of MTX was similar at initiation [14.4 (5.1) mg
per week] and month 6 [14.5 (5.1) mg per week].
Of the 99 patients with a change in MTX dose
during the study period, the mean (SD) dose
change was - 2.9 (5.5) mg per week. Overall,
30 patients had increases in MTX dose and 75
had decreases. The number of patients receiving
concomitant corticosteroids was 796/1912
(41.6%) at baseline and 615/1504 (40.9%) at
month 6. Of these patients, mean (SD) pred-
nisone-equivalent dose was 8.5 (5.4) mg per day
at baseline and 7.7 (4.9) mg per day at month 6.
Of the 217 patients with a change in corticos-
teroid dose during the study period, the mean
(SD) dose change was - 2.2 (9.0) mg per day.
Efficacy
Overall, mean (SD) DAS28 scores decreased
from baseline to month 6 [5.82 (1.24) to 2.65
(1.37)], with 69.8% of patients achieving DAS28
remission (DAS28\ 2.6, 52.8%) or low disease
activity (LDA; 2.6 B DAS28 B 3.2, 17.0%) at
month 6. The proportion of patients who
achieved DAS28 remission or LDA was similar
between biologic-naive (72.8%; remission:
55.6%; LDA: 17.1%) and biologic-exposed
(66.3%; remission: 49.4%; LDA: 16.9%)
patients.
Decreases in mean (SD) scores were reported
for all patient- and physician-reported out-
comes, which included patient assessment of
RA pain [- 32.4 (28.8) mm], patient assessment
of disease activity [- 32.8 (28.6) mm], patient
assessment of morning stiffness [- 31.8 (30.1)
mm], physician assessment of disease activity
[- 36.0 (26.0) mm], and HAQ-DI score [- 0.6
(0.7)]; changes were similar between biologic-
naive and biologic-exposed patients (Fig. 3).
The number of patients with morning stiffness
decreased from 1368/1482 (92.3%) at baseline
to 591/981 (60.2%) at month 6. At baseline,
50.0% of patients reported[60 min of morn-
ing stiffness daily, 30.4% had 30 to 60 min, and
19.6% had\ 30 min. At 6 months, 21.1%
had[ 60 min of morning stiffness daily, 26.4%
had 30 to 60 min, and 52.3% had\30 min
(Fig. 4). Patients who were biologic naive
showed numerically better improvement in all
PROs than patients who were biologic exposed.
A meaningful reduction (C 0.22) in HAQ-DI
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Table 1 Baseline demographics and disease characteristics













Age, years 51.7 (13.4) 54.9 (13.3) 54.5 (13.3) 52.4 (13.4) 53.1 (13.4)
Female, n (%) 881 (82.2) 698 (83.2) 512 (80.3) 1067 (83.8) 1579 (82.6)
Male, n (%) 191 (17.8) 141 (16.8) 126 (19.7) 206 (16.2) 332 (17.4)
Duration of RA, years 6.9 (7.4) 11.4 (9.9) 9.7 (10.0) 8.5 (8.3) 8.9 (8.9)
Duration of TCZ treatment,
days
176.8 (74.9) 212.1 (88.5) 188.5 (83.9) 194.2 (82.5) 192.3 (83.0)
Patient assessment of RA pain
on VAS, mm
62.3 (23.0) 64.2 (22.4) 63.6 (22.6) 63.0 (22.9) 63.2 (22.8)
Patient assessment of disease
activity on VAS, mm
63.4 (22.7) 66.1 (21.7) 65.6 (21.0) 64.2 (22.8) 64.6 (22.2)
Patient assessment of fatigue
on VAS, mm
57.3 (26.2) 63.0 (24.0) 59.2 (25.2) 59.7 (25.7) 59.6 (25.5)
Patient assessment of morning
stiffness on VAS, mm
54.0 (27.8) 58.3 (26.1) 56.4 (26.0) 55.5 (27.7) 55.8 (27.2)
Patients with morning
stiffness, n (%)
763 (91.9) 605 (92.8) 424 (92.0) 944 (92.5) 1368 (92.3)
Physician assessment of
disease activity on VAS, mm
58.9 (22.1) 60.4 (21.4) 58.2 (22.6) 60.2 (21.4) 59.6 (21.8)
HAQ-DIb 1.6 (0.8) 1.6 (0.7) 1.6 (0.8) 1.6 (0.8) 1.6 (0.8)
DAS28c 6.0 (1.3) 5.7 (1.2) 5.7 (1.3) 5.9 (1.2) 5.8 (1.2)
CDAI 33.6 (14.7) 32.2 (13.4) 31.8 (14.1) 33.7 (14.3) 33.1 (14.2)
SDAI 36.9 (16.2) 34.6 (14.2) 34.3 (15.4) 36.6 (15.4) 35.9 (15.4)
TJC28 12.5 (7.7) 11.4 (7.3) 11.0 (7.4) 12.5 (7.6) 12.0 (7.5)
SJC28 8.8 (6.6) 7.3 (5.8) 7.6 (6.1) 8.4 (6.3) 8.1 (6.3)
ESR, mm/h 45.9 (31.9) 36.3 (26.3) 41.2 (30.6) 42.1 (29.7) 41.8 (30.0)
CRP, mg/l 30.7 (47.3) 22.1 (29.3) 24.8 (35.6) 27.9 (42.8) 26.9 (40.6)
CDAI clinical disease activity index, CRP C-reactive protein, DAS28 Disease Activity Score using 28 joints, ESR erythrocyte
sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, SDAI simpliﬁed disease activity index,
SJC28 swollen joint count at 28 joints, TCZ tocilizumab, TJC28 tender joint count at 28 joints, VAS visual analog scale
a Except where otherwise indicated
b HAQ-DI data from Belgian patients were excluded because of use of an alternative scoring system
c DAS28-ESR or, if missing, DAS28-CRP
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from baseline to month 6 was achieved by
68.9% of patients overall. The proportions of
biologic-naive and biologic-exposed patients
who had a meaningful reduction in HAQ-DI
were 74.8% and 62.3%, respectively.
Safety
Of the total study population, 817 patients
(42.7%) experienced C 1 AE [179 events per 100
patient-years (PY)] and 118 patients (6.2%)
experienced an SAE (17 events per 100 PY). The
most common AEs (affecting C 5% of patients)
Fig. 2 Kaplan-Meier curves of duration on tocilizumab (TCZ; ﬁrst to last dose) stratiﬁed by biologic exposure at baseline
(a) and by TCZ treatment (b)
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were from the following system organ classes:
infections and infestations (13.9% of patients),
abnormal laboratory findings (investigations)
(11.3%), musculoskeletal and connective tissue
disorders (6.3%), gastrointestinal disorders
(5.9%), skin and subcutaneous tissue disorders
(5.6%), and blood and lymphatic system disor-
ders (5.5%) (Table 3). A total of 382 patients
(20.0%) experienced AEs that were determined
by the investigator to be related to treatment
(58 per 100 PY). AEs resulted in withdrawal from
the study in 104 patients (5.4%). The most
common SAEs (affecting C 1% of patients) were
from the system organ class infections and
infestations, reported in 35 patients (1.8%).
Eight deaths occurred during the study, with
the causes reported to be one each of
pneumonia, sepsis, pulmonary edema, respira-
tory failure, arrhythmia, malignant lung neo-
plasm, cerebrovascular accident, and shock; the
report of respiratory failure was suspected by the
investigator to be related to TCZ treatment. AEs
and SAEs were reported in 34.2% and 4.9% of
biologic-naive patients and in 53.6% and 7.7%
of biologic-exposed patients, respectively. AEs
and SAEs were reported in 47.1% and 7.4% of
patients in the TCZ monotherapy group and in
40.5% and 5.6% of patients in the combination
therapy group, respectively.
DISCUSSION
This multi-national, observational study evalu-
ated the efficacy, safety, and patterns of usage
with TCZ over a 6-month period in patients
with RA. This analysis extends prior findings
from an interim report [19] to provide a com-
plete data set with a total of 1912 patients and
describes PROs and other clinical outcomes
among patients who were biologic naive vs.
biologic experienced at baseline.
Analysis of treatment patterns in routine
clinical practice showed that 51.6% of patients
initiated TCZ as their first biologic and, overall,
most patients (81.2%) remained on TCZ at
month 6. Retention rates were similar for
patients who were biologic naive vs. biologic
exposed and are consistent with previous real-
world reports [19, 21–23] and with that
observed in our interim results (82.9%) [19]. A
decrease in the use of concomitant csDMARDs
was observed; although the overall mean (SD)
dose of MTX among all patients receiving MTX
was similar from baseline to month 6 [14.4 (5.1)
mg per week to 14.5 (5.1) mg per week], the
proportion of patients receiving concomitant
MTX decreased from 47.8% at baseline to 43.0%
at month 6. In addition, patients with a change
in MTX dose showed a reduction in weekly dose
from baseline to month 6 [mean (SD) change,
- 2.9 (5.5) mg]. This pattern of decreased con-
comitant csDMARD use may be an indirect
measure of the effectiveness of TCZ. The
observational FIRST Bio study of biologic-naive
patients with RA initiating TCZ also reported a
reduction in both the proportion of patients













812 (75.7) 541 (64.5) 1353 (70.8)
Methotrexate
Baseline, n (%) 553 (51.5) 361 (43.0) 914 (47.8)
Dose at baseline,
mean (SD), g
13.6 (4.7) 15.6 (5.4) 14.4 (5.1)
Month 6, n (%) 375 (34.9) 272 (32.4) 647 (33.8)
Dose at month 6,
mean (SD), g
13.8 (4.9) 15.3 (5.3) 14.5 (5.1)
Corticosteroids
Baseline, n (%) 410 (38.2) 386 (46.0) 796 (41.6)
Dose at baseline,
mean (SD), ga
8.8 (5.6) 8.1 (5.1) 8.5 (5.4)
Month 6, n (%) 309 (28.8) 306 (36.5) 615 (32.2)
Dose at month 6,
mean (SD), ga
7.6 (4.6) 7.7 (5.2) 7.7 (4.9)
DMARD disease-modifying antirheumatic drug
a Prednisone equivalent
Rheumatol Ther (2019) 6:231–243 237
receiving concomitant MTX and the MTX dose
at month 6 [9].
Given the AE profile and comorbidity risks of
corticosteroids, current European League
Against Rheumatism guidelines for the treat-
ment of RA recommend that corticosteroids be
tapered as rapidly as clinically feasible [24].
Thus, the use of corticosteroids is an important
consideration when evaluating the efficacy of
RA therapies. In our current analysis, a small
decrease in mean (SD) daily dose of corticos-
teroids from baseline to month 6 was observed
[8.5 (5.4)–7.7 (4.9) mg]. This finding is consis-
tent with what we have reported previously
using interim data from this study (TCZ
monotherapy, 8.4–7.7 mg per day; TCZ combi-
nation therapy, 8.4–7.6 mg per day) [19]. In
addition, patients in the present analysis with
any change in corticosteroid dose had an over-
all reduction in daily dose from baseline to
Fig. 3 Changes in quality-of-life outcomes from baseline to month 6. RA rheumatoid arthritis, VAS visual analog scale.
Error bars denote standard deviation
Fig. 4 Duration of morning stiffness at baseline and month 6
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month 6 [mean (SD) change, - 2.2 (9.0) mg].
Corticosteroid-sparing effects of TCZ have sim-
ilarly been observed in other real-world studies
of TCZ use in routine practice conducted in
Japan [9], France [25, 26], Australia [27], Ger-
many [28], and the USA [29]. Together, these
findings show that both TCZ monotherapy and
combination therapy reduce the need for cor-
ticosteroids in patients with RA.
Mean DAS28 scores decreased from baseline
to month 6, with comparable improvements in
patients receiving TCZ monotherapy and com-
bination therapy. The overall rate of remission
by DAS28 score at 6 months was 52.8% and is
consistent with DAS28 remission rates reported
after 6 months of treatment with TCZ in real-
world studies [21, 30] and in clinical trials
[31, 32]. These findings suggest that the
administration of DMARDs in combination
with TCZ may not add additional clinical ben-
efit over TCZ as monotherapy, which may
reduce the exposure of patients to unnecessary
added therapy. Similar rates of remission were
also observed in patients who were biologic
naive vs. biologic exposed, consistent with a
recent study from the British Society of
Rheumatology Biologics Register that found no
significant difference in DAS28 remission
between patients with RA initiating TCZ who
were biologic naive and those who were bio-
logic experienced [23]. In contrast, the real-
world ACT-LIFE study found a significantly
greater improvement in DAS28 at 6 months in
patients treated with TCZ who were biologic
naive vs. those who were biologic experienced
[21]. Group differences in DAS28 response in
the ACT-LIFE study may be explained in part by
differences in disease severity at baseline
between biologic-naive and biologic-experi-
enced patients.
PROs are an integral component of under-
standing the impact of disease and treatment on
symptoms, functioning, and other outcomes. In
our current analysis, improvements were
observed for all PROs, including patient assess-
ment of pain and morning stiffness, patient and
physician assessment of disease activity, and
HAQ-DI score. Improvements in PROs are
associated with an increased ability to partici-
pate in daily activities, including work and lei-
sure pursuits, improved social and psychologic
functioning, decreased pain, and an overall
improvement in QOL [33]. Although no signif-
icant differences were found in the mean
changes in scores between biologic-naive and
biologic-exposed patients, biologic-naive
patients had numerically greater improvement
in all PROs, except for physician-reported out-
come of disease activity, than patients who were
biologic exposed. A real-world comparison of
patients in the British Society of Rheumatology
Biologics Register registry receiving TCZ as a
first-line vs. subsequent-line biologic found that
biologic-naive patients had a significantly
greater improvement in HAQ score at 6 months
and achieved the minimal clinically important
difference in HAQ at a higher rate than in
patients who were biologic exposed [23]. In
contrast, an analysis of patients with RA in the
US Corrona registry found numerically similar
improvements with TCZ in most PROs between
Table 3 Adverse events (AEs) by system organ classa
Body system AE,














90 (8.4) 175 (20.9) 265 (13.9)




44 (4.1) 77 (9.2) 121 (6.3)
Gastrointestinal
disorders








54 (5.0) 51 (6.1) 105 (5.5)
All body systems 367 (34.2) 450 (53.6) 817 (42.7)
a Reported in C 5% of all patients
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patients who were TNFi naive or TNFi exposed.
In that study, 70.9% of TNFi-naive patients had
previously received at least one non-TNFi bio-
logic [34].
The safety profile of TCZ in this study was
consistent with previous findings; no new AEs
were reported [35, 36]. The most common AEs
and SAEs were infections and infestations,
which was consistent with our interim findings
[19] and with previous clinical trials of TCZ
[35, 36]. No difference in the frequency of AEs
was observed between patients who received
TCZ monotherapy and those who received
combination therapy. A meta-analysis of TCZ
clinical trials [37] and the French real-world
ACT-SOLO study [38] similarly found no dif-
ference in the frequency of AEs in patients
receiving TCZ monotherapy vs. combination
therapy. Rates of AEs and SAEs were numerically
more frequent in biologic-exposed patients
than biologic-naive patients. This corresponds
with what has been observed in a clinical trial of
TCZ comparing AEs and SAEs in patients with a
prior inadequate response to TNFi (TNFi-IR)
with those in patients who were TNFi naive.
Results from the trial showed a higher fre-
quency of AEs and SAEs in patients with TNFi-IR
than in those who were TNFi naive [32]. This
difference in the frequency of events might be
partly attributable to the longer disease dura-
tion or increased concomitant use of corticos-
teroids in patients with TNFi-IR, or to other
factors, such as more frequent use of concomi-
tant medications, that have been associated
with TNFi-IR [39].
This study was not without limitations.
Because this was a non-interventional study,
TCZ dose, frequency, and duration were not
dictated by the study protocol. This inevitably
resulted in some variation between patients.
The study population was restricted to patients
receiving intravenous TCZ, preventing conclu-
sions about subcutaneous TCZ treatment. The
largest proportion of patients were from China,
where the duration of TCZ treatment was lim-
ited because of financial reasons. Finally, the
comparison of biologic-naive vs. biologic-expe-
rienced subgroups was performed as a post hoc
analysis, and comparisons between subgroups
are restricted to descriptive terms.
CONCLUSION
This large, multi-national, non-interventional
study indicates that both TCZ monotherapy
and TCZ combination therapy are safe, effec-
tive, and well tolerated in patients with RA,
with demonstrable improvement in patient-
and physician-reported outcomes. These
improvements occurred irrespective of patients’
biologic treatment history.
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